Stuart Gander

Chief Executive Officer

C-suiteM

FI·FIN-FSA

Q-linea AB (publ)Q-linea AB (publ)

0

Total declarations

0

Companies

—

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

Explore the full record of transactions filed by Stuart Gander, Chief Executive Officer. Director active across 2 companies, notably Q-linea AB (publ). In total, 2 disclosures have been logged. The latest transaction was filed on 9 June 2025 — Purchase. Regulator: FIN-FSA. The full history is openly available.

Declarations2 total

Executives●PurchaseQQ-linea AB (publ)29FIN-FSA

S

Stuart GanderVerkställande direktör (VD)

€11,7842,500,000 shares@ €0.00470.0039% mcap61.9% of flow

Aktie

FI:A003P626-1·9 Jun 2025

Ideal exit: 6 Mar 2026 (T+270)

FIN-FSA ↗

Executives●PurchaseQQ-linea AB (publ)27FIN-FSA

S

Stuart GanderVerkställande direktör (VD)

€7,26740,000,000 shares@ €0.00020.0024% mcap38.1% of flow

Option

FI:A003O534-1·15 May 2025

Ideal exit: 9 Feb 2026 (T+270)

FIN-FSA ↗

2 of 2 declarations

About Stuart Gander

Stuart Gander is the CEO of Q-linea AB, an innovative company in the medical technology field. As CEO, he is responsible for the strategic direction of the company and the management of its daily operations. His leadership is essential in guiding Q-linea towards its growth and innovation objectives. The company focuses on developing advanced diagnostic solutions.